Pending NDAs To Be Poussot’s Top Priority As Wyeth’s Upcoming CEO
Executive Summary
Upon assuming the role of Wyeth President and CEO in January, Bernard Poussot will make his top priority the approval of the seven applications pending FDA review decisions, Poussot said during the firm's third quarter earnings call Oct. 18
You may also be interested in...
Wyeth Finally Cleared For Pristiq Lift-Off, But With Lower Dose
Approval of Wyeth's Pristiq (desvenlafaxine) comes at the lower dose that was submitted late in the review process and with a request for a postmarketing study to determine if even lower doses would be effective
Wyeth Finally Cleared For Pristiq Lift-Off, But With Lower Dose
Approval of Wyeth's Pristiq (desvenlafaxine) comes at the lower dose that was submitted late in the review process and with a request for a postmarketing study to determine if even lower doses would be effective
Tablet & Teva Block Sun As Generic Competition For Wyeth’s Effexor XR
Wyeth is anticipating it will be able to block entry of Sun Pharmaceuticals' generic version of Effexor XR because of the brand firm's existing deal with first-to-file Teva and the alternate venlafaxine dosage form that Sun is using in its ANDA